Antibodies, like many other natural proteins, are normally decorated with sugars. Optimizing the pattern of sugars associated with synthetic antibodies can have an enormous impact on their therapeutic efficacy. This technology, known as glycoengineering, is the focus of the Roche research centre in Schlieren, Switzerland.